CD74 and MIF in EBV-associated malignancies: diagnostic and therapeutic implications
CD74 and its ligand, macrophage migration inhibitory factor (MIF), are highly expressed in several malignancies and contribute to tumor progression, making them attractive targets for cancer diagnosis and therapy. However, the expression of CD74 and MIF and their clinicopathological significance remain unclear in Epstein–Barr virus (EBV)-associated malignancies, including nasopharyngeal carcinoma (NPC) and extranodal natural killer/T-cell lymphoma, nasal type (ENKL). In the present study, we demonstrated that CD74 was predominantly expressed by tumor cells in NPC and ENKL tissues. High CD74 expression in NPC was significantly associated with EBV infection. In addition, serum MIF levels were significantly elevated in patients with NPC and ENKL and showed good diagnostic performance in distinguishing patients from healthy controls. Elevated serum MIF levels were also associated with the presence of B symptoms in patients with ENKL. Furthermore, EBV-positive NPC and ENKL cell lines expressed cell-surface CD74 and secreted MIF in a time-dependent manner. Treatment with a CD74-neutralizing antibody significantly reduced the viability of these cell lines, suggesting that CD74/MIF signaling contributes to tumor growth, possibly through an autocrine mechanism. CD74 knockdown in NPC cells induced transcriptomic alterations involving immune- and inflammation-related pathways. Notably, treatment with an anti-CD74 antibody significantly suppressed the growth of established NPC xenografts in mice. Collectively, these findings suggest that CD74 and MIF represent promising diagnostic biomarkers and that therapeutic strategies targeting the CD74/MIF axis may provide a novel treatment approach for EBV-associated malignancies, particularly NPC and ENKL.
Authors
- Risa Wakisaka (ORCID: https://orcid.org/0000-0002-9238-4034)
- Hiroki Komatsuda (ORCID: https://orcid.org/0000-0002-3783-2746)
- Shota Sakaue (ORCID: https://orcid.org/0009-0002-1348-3331)
- Hisataka Ominato (ORCID: https://orcid.org/0000-0003-4826-9829)
- Miki Takahara (ORCID: https://orcid.org/0000-0003-0535-5778)
- Toshihiro Nagato (ORCID: https://orcid.org/0000-0001-8326-8296)
- Michihisa Kono (ORCID: https://orcid.org/0000-0002-8506-928X)
- Ryosuke Sato (ORCID: https://orcid.org/0000-0001-5899-3410)
- Ryusuke Hayashi (ORCID: https://orcid.org/0000-0002-9868-2286)
- Takumi Kumai (ORCID: https://orcid.org/0000-0002-3411-671X)
- Akemi Kosaka (ORCID: https://orcid.org/0000-0001-5599-3685)
- Kan Kishibe (ORCID: https://orcid.org/0000-0003-4830-2051)
- Takayuki Ohkuri (ORCID: https://orcid.org/0000-0002-6889-7809)
- Ryusei Yoshino (ORCID: https://orcid.org/0000-0002-6904-7267)
- Hidekiyo Yamaki (ORCID: https://orcid.org/0009-0004-0838-9396)
- Kenzo Ohara (ORCID: https://orcid.org/0000-0002-6957-6206)
- Takahiro Inoue (ORCID: https://orcid.org/0009-0006-2457-9063)
- Tatsuya Hayashi
- Hiroya Kobayashi
- Hiroyoshi Nozaki
Institutions
- Asahikawa Medical University (JP)
- Asahikawa University (JP)
Publication Details
- Journal
- Cancer Immunology Immunotherapy
- Published
- 2026-11-18
- DOI
- https://doi.org/10.1007/s00262-026-04620-8
- Primary Topic
- Viral-associated cancers and disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Asahikawa Medical University
- Japan Society for the Promotion of Science